Arabinosyltransferase C Mediates Multiple Drugs Intrinsic Resistance by Altering Cell Envelope Permeability in Mycobacterium abscessus

Mycobacterium abscessus is intrinsically resistant to most antibiotics, and treatment of its infections is highly challenging. The mechanisms of its intrinsic resistance remain not fully understood. ABSTRACT Mycobacterium abscessus is an emerging human pathogen leading to significant morbidity and even mortality, intrinsically resistant to almost all the antibiotics available and so can be a nightmare. Mechanisms of its intrinsic resistance remain not fully understood. Here, we selected and confirmed an M. abscessus transposon mutant that is hypersensitive to multiple drugs including rifampin, rifabutin, vancomycin, clofazimine, linezolid, imipenem, levofloxacin, cefoxitin, and clarithromycin. The gene MAB_0189c encoding a putative arabinosyltransferase C was found to be disrupted, using a newly developed highly-efficient strategy combining next-generation sequencing and multiple PCR. Furthermore, selectable marker-free deletion of MAB_0189c recapitulated the hypersensitive phenotype. Disruption of MAB_0189c resulted in an inability to synthesize lipoarabinomannan and markedly enhanced its cell envelope permeability. Complementing MAB_0189c or M. tuberculosis embC restored the resistance phenotype. Importantly, treatment of M. abscessus with ethambutol, a first-line antituberculosis drug targeting arabinosyltransferases of M. tuberculosis, largely sensitized M. abscessus to multiple antibiotics in vitro. We finally tested activities of six selected drugs using a murine model of sustained M. abscessus infection and found that linezolid, rifabutin, and imipenem were active against the MAB_0189c deletion strain. These results identified MAB_0189 as a crucial determinant of intrinsic resistance of M. abscessus, and optimizing inhibitors targeting MAB_0189 might be a strategy to disarm the intrinsic multiple antibiotic resistance of M. abscessus. IMPORTANCE Mycobacterium abscessus is intrinsically resistant to most antibiotics, and treatment of its infections is highly challenging. The mechanisms of its intrinsic resistance remain not fully understood. Here we found a transposon mutant hypersensitive to a variety of drugs and identified the transposon inserted into the MAB_0189c (orthologous embC coding arabinosyltransferase, EmbC) gene by using a newly developed rapid and efficient approach. We further verified that the MAB_0189c gene played a significant role in its intrinsic resistance by decreasing the cell envelope permeability through affecting the production of lipoarabinomannan in its cell envelope. Lastly, we found the arabinosyltransferases inhibitor, ethambutol, increased activities of nine selected drugs in vitro. Knockout of MAB_0189c made M. abscessus become susceptible to 3 drugs in mice. These findings indicated that potential powerful M. abscessus EmbC inhibitor might be used to reverse the intrinsic resistance of M. abscessus to multiple drugs.

[1]  D. Wei,et al.  Improving the biotransformation of phytosterols to 9α-hydroxy-4-androstene-3,17-dione by deleting embC associated with the assembly of cell envelope in Mycobacterium neoaurum. , 2020, Journal of biotechnology.

[2]  G. Besra,et al.  Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol , 2020, Science.

[3]  L. Kremer,et al.  Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus , 2020, Nature Reviews Microbiology.

[4]  Guoliang Zhang,et al.  Assessment of Clofazimine and TB47 Combination Activity against Mycobacterium abscessus Using a Bioluminescent Approach , 2019, Antimicrobial Agents and Chemotherapy.

[5]  S. Shin,et al.  Rifabutin Is Active against Mycobacterium abscessus in Mice , 2019, Antimicrobial Agents and Chemotherapy.

[6]  L. Chiarelli,et al.  Mycobacterium abscessus, an Emerging and Worrisome Pathogen among Cystic Fibrosis Patients , 2019, International journal of molecular sciences.

[7]  Md. Mahmudul Islam,et al.  Comparative Analysis of Whole-Genome and Methylome Profiles of a Smooth and a Rough Mycobacterium abscessus Clinical Strain , 2019, G3: Genes, Genomes, Genetics.

[8]  G. Lamichhane,et al.  Synergistic Efficacy of β-Lactam Combinations against Mycobacterium abscessus Pulmonary Infection in Mice , 2019, Antimicrobial Agents and Chemotherapy.

[9]  Tianyu Zhang,et al.  The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model , 2019, Nature Communications.

[10]  P. Sander,et al.  The Role of Antibiotic-Target-Modifying and Antibiotic-Modifying Enzymes in Mycobacterium abscessus Drug Resistance , 2018, Front. Microbiol..

[11]  K. Becker,et al.  Lipoprotein Glycosylation by Protein-O-Mannosyltransferase (MAB_1122c) Contributes to Low Cell Envelope Permeability and Antibiotic Resistance of Mycobacterium abscessus , 2017, Front. Microbiol..

[12]  L. Kremer,et al.  Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and Is Effective in Infected Zebrafish , 2017, Antimicrobial Agents and Chemotherapy.

[13]  H. Kwon,et al.  Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus , 2017, Antimicrobial Agents and Chemotherapy.

[14]  G. Lamichhane,et al.  Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus. , 2017, Future Microbiology.

[15]  E. Böttger,et al.  Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591 , 2017, The Journal of antimicrobial chemotherapy.

[16]  Mithila Rajagopal,et al.  Multidrug Intrinsic Resistance Factors in Staphylococcus aureus Identified by Profiling Fitness within High-Diversity Transposon Libraries , 2016, mBio.

[17]  Y. Liu,et al.  Identification of Lysine Acetylation in Mycobacterium abscessus Using LC-MS/MS after Immunoprecipitation. , 2016, Journal of proteome research.

[18]  Y. Hamada,et al.  Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms , 2016, Antimicrobial Agents and Chemotherapy.

[19]  G. Besra,et al.  Assembly of the Mycobacterial Cell Wall. , 2015, Annual review of microbiology.

[20]  Po-Ren Hsueh,et al.  Mycobacterium abscessus Complex Infections in Humans , 2015, Emerging infectious diseases.

[21]  A. Diacon,et al.  Combinations of β-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis Infection , 2015, Antimicrobial Agents and Chemotherapy.

[22]  Alyaa M. Abdel-Haleem,et al.  Essential Role of the ESX-5 Secretion System in Outer Membrane Permeability of Pathogenic Mycobacteria , 2015, PLoS genetics.

[23]  A. Camilli,et al.  Genetic Basis of Persister Tolerance to Aminoglycosides in Escherichia coli , 2015, mBio.

[24]  L. Kremer,et al.  β-Lactamase inhibition by avibactam in Mycobacterium abscessus. , 2014, The Journal of antimicrobial chemotherapy.

[25]  A. Korkegian,et al.  Mutations in the Essential Arabinosyltransferase EmbC Lead to Alterations in Mycobacterium tuberculosis Lipoarabinomannan* , 2014, The Journal of Biological Chemistry.

[26]  R. Zare,et al.  LprG-Mediated Surface Expression of Lipoarabinomannan Is Essential for Virulence of Mycobacterium tuberculosis , 2014, PLoS pathogens.

[27]  J. Mainardi,et al.  Characterization of broad-spectrum Mycobacterium abscessus class A β-lactamase. , 2014, The Journal of antimicrobial chemotherapy.

[28]  B. Gicquel,et al.  Mycobacterium abscessus: a new antibiotic nightmare. , 2012, The Journal of antimicrobial chemotherapy.

[29]  Jay Shendure,et al.  Genome-Scale Identification of Resistance Functions in Pseudomonas aeruginosa Using Tn-seq , 2011, mBio.

[30]  Young Kil Park,et al.  Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. , 2009, American journal of respiratory and critical care medicine.

[31]  S. Holland,et al.  Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. , 2009, Respiratory medicine.

[32]  W. Jacobs,et al.  Lipoprotein Processing Is Essential for Resistance of Mycobacterium tuberculosis to Malachite Green , 2009, Antimicrobial Agents and Chemotherapy.

[33]  K. Nash,et al.  A Novel Gene, erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates of Mycobacterium abscessus but Is Absent from Mycobacterium chelonae , 2009, Antimicrobial Agents and Chemotherapy.

[34]  T. Parish,et al.  The Critical Role of embC in Mycobacterium tuberculosis , 2008, Journal of bacteriology.

[35]  J. Casanova,et al.  Importance of T Cells, Gamma Interferon, and Tumor Necrosis Factor in Immune Control of the Rapid Grower Mycobacterium abscessus in C57BL/6 Mice , 2007, Infection and Immunity.

[36]  N. Ampel Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases , 2007 .

[37]  G. Hatfull,et al.  Recombineering in Mycobacterium tuberculosis , 2007, Nature Methods.

[38]  K. Khoo,et al.  The Emb proteins of mycobacteria direct arabinosylation of lipoarabinomannan and arabinogalactan via an N‐terminal recognition region and a C‐terminal synthetic region , 2003, Molecular microbiology.

[39]  E. Rubin,et al.  Genes required for mycobacterial growth defined by high density mutagenesis , 2003, Molecular microbiology.

[40]  R. Wallace,,et al.  Clinical and Taxonomic Status of Pathogenic Nonpigmented or Late-Pigmenting Rapidly Growing Mycobacteria , 2002, Clinical Microbiology Reviews.

[41]  K. Khoo,et al.  The Role of the embA and embB Gene Products in the Biosynthesis of the Terminal Hexaarabinofuranosyl Motif of Mycobacterium smegmatisArabinogalactan* , 2001, The Journal of Biological Chemistry.

[42]  E. Rubin,et al.  Comprehensive identification of conditionally essential genes in mycobacteria , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A. Telenti,et al.  Role of embB in natural and acquired resistance to ethambutol in mycobacteria , 1997, Antimicrobial agents and chemotherapy.

[44]  L. Kremer,et al.  b-Lactamase inhibition by avibactam in Mycobacterium abscessus , 2015 .